No Surprises - Corcept Therapeutics
Bioportfolio,
We expect The Pancreatic Cancer trial decision to be announced with updated results at ASCOin early June 2019.
We expect The Pancreatic Cancer trial decision to be announced with updated results at ASCOin early June 2019.
1. Preventing Hypokalemia in Korlym Patients with ACTH-Dependent Cushing’s Syndrome 2.
We previously discussed the modest but steady growth in net sales revenues, and this quarter affirms the description.
On Thursday, January 31, 2019, Corcept Therapeutics reportedpreliminary Q4-2018 results and guidance.